Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI France ETF (EWQ) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

iShares MSCI France ETFTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI France ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares MSCI France ETF trades at $47.49, while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while iShares MSCI France ETF pays none, and iShares MSCI France ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.

EWQZBH
Sector
Broad Market / FactorHealth
52-Week High
$48.35$107.71
52-Week Low
$41.68$79.58
Market Cap
$18.55B
Enterprise Value
$25.61B
Dividend Yield
0.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI France ETF

EWQ (iShares MSCI France ETF) trades at $47.51, down 0.5% on the day, with a bullish technical signal driven by moving averages. The ETF offers exposure to French equities with a 15.3x P/E ratio and favorable PEG of 1.6x according to Seeking Alpha (August 4, 2026). Recent institutional activity shows Allspring Global reduced its position by 26.2% in Q1 2026, while European central bank policy remains a key market driver.

The outlook for EWQ remains positive with French stocks hitting new highs and attractive valuations supporting further upside. Key risks include ECB monetary policy uncertainty amid Middle East tensions and potential production constraints at French nuclear facilities. The concentrated industrial sector exposure (32%) provides growth potential but increases sector-specific vulnerability.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $97.9, up 0.12% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology. Key financials show a P/E of 23.6 and net income margin of 9.48%, while cash flow from operations improved to $1.70B in 2025.

The outlook is positive, with a consensus price target of $103.56 offering ~6% upside. Risks include competitive pressures and margin volatility, but consistent earnings beats and institutional accumulation support a constructive view for long-term investors.

Returns comparison

Trailing returns across standard periods

About iShares MSCI France ETF

EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.

Read more on EWQ

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH